

ConSaRGhent – Consortium for Sarcoma Research Ghent

Publications (last updated March 2024)

Generation of post-surgical minimal residual disease models to investigate metastasis in soft tissue sarcoma patient-derived orthotopic xenografts. Fischer, S., Creytens, D., Gijssels, S., Descamps, B., Lapeire, L., Hendrix, A., Sys, G., & De Wever, O. (2024). STAR protocols, 5(1), 102863.

RAF1-rearranged Spindle Cell Mesenchymal Tumor With Calcification and Heterotopic Ossification: A Case Report and Review of Literature. Cordier, F., Loontjens, S., Van der Meulen, J., Lapeire, L., van Ramshorst, G. H., Sys, G., Van Dorpe, J., & Creytens, D. International journal of surgical pathology (2024), 32(1), 133–139.

Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI: development and external validation of a model. Kalisvaart, G. M., Van Den Berghe, T., Grootjans, W., Lejoly, M., Huysse, W. C. J., Bovée, et al (including Creytens, D., Lapeire, L., Sys, G.) Skeletal radiology (2024), 53(2), 319–328.

Wait-and-scan: an alternative for curettage in atypical cartilaginous tumours of the long bones. Scholte CHJ, Dorleijn DMJ, Krijvenaar DT, van de Sande MAJ, van Langevelde K. The bone and Joint Journal, Bone Joint Journal (2024) Jan 1;106-B(1):86-92.

Post-operative minimal residual disease models to study metastatic relapse in soft-tissue sarcoma patient-derived xenografts. Fischer S, Creytens D, De Geyter S, De Vlieghe E, Pattyn P, Bekaert SL, Durinck K, Van Roy N, Hendrix A, Lapeire L, Sys G, De Wever O. Clin Transl Med (2023) 13(6):e1290.

Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 . Trial. Koch R, Haveman L, Ladenstein R, Brichard B, Jürgens H, Cyprova S, et al (including Dhooge C) Clin Cancer Res. (2023) Dec 15;29(24):5057-5068.

High-grade endometrial stromal sarcoma-like' sarcoma in male: Does it exist? A case report and review of the literature. Cordier, F., Van der Meulen, J., Loontjens, S., Van Roy, N., Lapeire, L., Willaert, W., Ferdinande, L., Van de Vijver, K., Van Dorpe, J., & Creytens, D. Pathology, research and practice (2023), 241, 154228.

Follow-up after curative surgical treatment of soft-tissue sarcoma for early detection of recurrence: which patients have more or fewer visits than advised in guidelines? Kruiswijk AA, Kuhrij-Kingma LS, Dorleijn DMJ, van de Sande MAJ, Van Bodegom-Vos L, Marang- van de Mheen PJ. Cancers (Basel) (2023) Sep 18;15(18):4617.

Health-Related Quality of Life of Bone and Soft-Tissue Tumor Patients around the Time of Diagnosis. Kruiswijk AA, Dorleijn DMJ, Marang-van de Mheen PJ, van de Sande MAJ, van Bodegom-Vos L. Cancers (Basel). (2023) May 17;15(10):2804.

Nirogacestat, a γ -Secretase Inhibitor for Desmoid Tumors. Gounder, M., Ratan, R., Alcindor, T., Schöffski, P., van der Graaf, W. T., Wilky, et al (including Lapeire, L). The New England journal of medicine (2023), 388(10), 898–912.

Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma. Budde A, Baust K, Weinhold L, Bernstein M, Bielack S, Dhooge C, Hjorth L, Janeway K, Jenney M, D. Krailo M et al. EUROPEAN JOURNAL OF CANCER (2022). 170. p.209-235

Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour. Georgiesh T, Aggerholm-Pedersen N, Schöffski P, Zhang Y, Napolitano A, Bovée JVMG, et al (including **Dorleijn D**). Br J Cancer. (2022) Nov;127(10):1793-1798.

Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly. Bleckman RF, Acem I, van Praag VM, **Dorleijn DMJ**, Verhoef C, Schrage YM, Haas RML, van de Sande MAJ, The Collaborative Persarc Research Group. Eur J Surg Oncol. (2022) May; 48(5)985-993

Efficacy of interdisciplinary rehabilitation in child cancer survivors : impact on physical fitness, fatigue and body composition after 1-year follow-up. Van Der Looven R, De Vos E, Vandekerckhove K, Coomans I, Laureys G and **Dhooge C**. (2022) EUROPEAN JOURNAL OF CANCER CARE. 31(6).

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Gounder, M. M., Razak, A. A., Somaiah, N., Chawla, S., Martin-Broto, J., Grignani, G, et al (including **Lapeire L**.) Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022), 40(22), 2479–2490.

Spindle cell/sclerosing rhabdomyosarcoma with a novel YAP1-MAML2 fusion in a 1-year-old: not all strongly TRK-expressing spindle cell sarcomas in infants are infantile fibrosarcomas!. **Cordier, F.**, Ameloot, E., **Dhooge, C.**, **Lapeire, L.**, **Sys, G.**, Van Dorpe, J., & **Creytens, D**. Pathology (2021), 53(7), 936–939.

Late Lung Metastasis in a Patient with a Clear Cell Chondrosarcoma: An Indication for a Life-Long Follow-Up?. West, P., **Jacobs, C.**, Saerens, M., **Creytens, D.**, **Sys, G.**, & **Lapeire, L**. Case reports in oncological medicine (2021) 7205649.

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. Saerens, M., Brusselaers, N., Rottey, S., Decruyenaere, A., **Creytens, D.**, & **Lapeire, L**. European journal of cancer (2021), 152, 165–182.

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center. Evenhuis RE, Acem I, Rueten-Budde AJ, Karis DSA, Fiocco M, **Dorleijn DMJ**, Speetjens FM, Anninga J, Gelderblom H, van de Sande MAJ. Cancers. (2021) Jan 27;13(3):486

NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature. Nuytemans, L., **Sys, G.**, **Creytens, D.**, & **Lapeire, L**. Acta clinica Belgica (2021). 76(2), 162–167.

A challenging case of a poorly differentiated small cell variant of synovial sarcoma with unusual immunophenotype. **Cordier, F.**, **Lapeire, L.**, **Sys, G.**, Van Dorpe, J., & **Creytens, D**. Pathology (2021). 53(5), 658–660.

Undifferentiated sarcoma of bone with a round to epithelioid cell phenotype harboring a novel EWSR1-SSX2 fusion identified by RNA-based next-generation sequencing. **Cordier, F.**, **Van der Meulen, J.**, Van Gaever, B., **Lapeire, L.**, **Sys, G.**, Van Dorpe, J., & **Creytens, D**. Genes, chromosomes & cancer (2022), 61(1), 44–49.

Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice. **Jacobs, C., & Lapeire, L.** Diagnostics (Basel, Switzerland) (2021), 11(3), 512.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Smeland S, Bielack S, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al (including **Dhooge C**). Eur J Cancer (2019) Mar;109:36-50.

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M. et al (including **Lapeire L.**). The Lancet. Oncology (2019) 20(8), 1148–1159.

Bone sarcomas : ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al (including **Dhooge C**). ANNALS OF ONCOLOGY (2018) . 29(suppl. 4). p.79-95

Retroperitoneal liposarcoma: current insights in diagnosis and treatment. **Matthyssens, L. E., Creytens, D., & Ceelen, W. P.** Frontiers in surgery (2015), 2, 4.

The in ovo CAM-assay as a xenograft model for sarcoma. **Sys, G., Lapeire, L.,** Stevens, N., Favoreel, H., Forsyth, R., Bracke, M., & **De Wever, O.** JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2013). (77).

Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick chorioallantoic membrane model. **Sys, G.,** Van Bockstal, M., Forsyth, R., Balke, M., Poffyn, B., Uyttendaele, D., Bracke, M., & **De Wever, O.** Cancer letters (2012), 326(1), 69–78.